| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Departments of Dermatology*
and
Pathology,
Free University Hospital,
Amsterdam, The Netherlands
Granzyme B (GrB) and T-cell-restricted intracellular antigen (TIA-1) are cytotoxic proteins that are specifically expressed by cytotoxic CD4 or CD8 positive T cells and natural killer cells. Recent studies demonstrated frequent expression of GrB and TIA-1 by neoplastic cells in primary cutaneous CD30+ large T-cell lymphomas and lymphomatoid papulosis but not in CD30- large T-cell lymphomas. In the present study, 74 biopsies from 54 patients with mycosis fungoides (MF) were investigated for the expression of GrB and TIA-1 using immunohistochemistry on paraffin sections. Staining of more than 10% of the neoplastic T cells for GrB or TIA-1 was considered positive. All but two follow-up biopsies had been obtained from patients without extracutaneous disease at the time of biopsy. Expression of TIA-1 and GrB was found in 33 (45%) and 14 (19%) of 74 MF biopsies, respectively. Comparison of biopsies from T3NoMo-stage MF (n = 27) and T2NoMo-stage MF (n = 45) showed increased expression of TIA-1 (55 versus 37%) and GrB (33 versus 9%) in T3NoMo-stage MF. Evaluation of multiple sequential biopsies from successive stages of MF also revealed an increase in the GrB/TIA-1 expression with tumor progression in five of eight cases. A clearcut relation between the expression of TIA-1 and/or GrB and the type of skin lesion biopsied was found. Considering all 74 biopsies, expression of TIA-1 and GrB was found in 18 of 50 (35%) and 5 of 50 (10%) patches or plaques, 9 of 16 (55%) and 3 of 16 (20%) tumors without blastic transformation, and 6 of 8 (75%) and 6 of 8 (75%) tumors with blastic transformation (defined as >50% blast cells). Correlation between GrB/TIA-1 expression in first diagnostic biopsies from patches or plaques from 40 patients with T2NoMo-stage MF and clinical follow-up data did not reveal differences in clinical behavior and survival between patients with (n = 14) or without (n = 26) expression of cytotoxic proteins, indicating that MF expressing cytotoxic proteins should not be considered as a separate group.
This article has been cited by other articles:
 |
|
 |
|
  N. Ortonne, D. Huet, C. Gaudez, A. Marie-Cardine, V. Schiavon, M. Bagot, P. Musette, and A. Bensussan Significance of circulating T-cell clones in Sezary syndrome Blood, May 15, 2006; 107(10): 4030 - 4038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Willemze, E. S. Jaffe, G. Burg, L. Cerroni, E. Berti, S. H. Swerdlow, E. Ralfkiaer, S. Chimenti, J. L. Diaz-Perez, L. M. Duncan, et al. WHO-EORTC classification for cutaneous lymphomas Blood, May 15, 2005; 105(10): 3768 - 3785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Krenacs, M. J. Smyth, E. Bagdi, T. Krenacs, L. Kopper, T. Rudiger, A. Zettl, H. K. Muller-Hermelink, E. S. Jaffe, and M. Raffeld The serine protease granzyme M is preferentially expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity Blood, May 1, 2003; 101(9): 3590 - 3593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. van Doorn, R. Dijkman, M. H. Vermeer, T. M. Starink, R. Willemze, and C. P. Tensen A Novel Splice Variant of the Fas Gene in Patients with Cutaneous T-Cell Lymphoma Cancer Res., October 1, 2002; 62(19): 5389 - 5392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Vermeer, R. van Doorn, D. Dukers, M. W. Bekkenk, C. J.L.M. Meijer, and R. Willemze CD8+ T Cells in Cutaneous T-Cell Lymphoma: Expression of Cytotoxic Proteins, Fas Ligand, and Killing Inhibitory Receptors and Their Relationship With Clinical Behavior J. Clin. Oncol., December 1, 2001; 19(23): 4322 - 4329. [Abstract] [Full Text]
|
|
|
|
 |
|
 D F Dukers, M H Vermeer, L H Jaspars, C A Sander, M J Flaig, W Vos, R Willemze, and C J L M Meijer Expression of killer cell inhibitory receptors is restricted to true NK cell lymphomas and a subset of intestinal enteropathy-type T cell lymphomas with a cytotoxic phenotype J. Clin. Pathol., March 1, 2001; 54(3): 224 - 228. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
